| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
PIISVYWK (10-100 μM; 48 hours) showed no cytotoxicity to bone marrow mesenchymal stem cells (BMMSCs) [1]. PIISVYWK (10-100 μM; 7 days) inhibited adipocyte differentiation of BMMSCs by inhibiting adipogenic transcription factors and adipogenic enzymes and enhancing lipolysis, with a lipid accumulation inhibition rate as high as 40.97% at a concentration of 100 μM [1]. PIISVYWK (10-100 μM; Nrf2 treatment for 2 days, HO-1 treatment for 3 days) activated the HO-1/Nrf2 signaling pathway in BMMSCs, increasing HO-1 cytoplasmic expression and Nrf2 nuclear expression at a concentration of 100 μM [1]. PIISVYWK (10-100 μM; 7 days) alleviates oxidative stress in bone marrow mesenchymal stem cells (BMMSCs) during adipogenesis by reducing reactive oxygen species (ROS) production and increasing antioxidant enzyme activity, with significant effects at a concentration of 100 μM [1]. PIISVYWK (10-100 μM; 7 days) alleviates the inflammatory response of BMMSCs by inhibiting the production of pro-inflammatory cytokines and regulating the MAPK pathway, with significant effects at a concentration of 100 μM [1]. PIISVYWK (100 μM; 7 days, pretreated with 5 μM ZnPP for 1 hour) exerts its anti-adipogenic effect on BMMSCs through HO-1 mediation, as ZnPP pretreatment can reverse its inhibitory effects on adipocyte differentiation, transcription factor expression, and lipolysis [1]. PIISVYWK (100 μM; 7 days, pretreated with 5 μM ZnPP for 1 hour) exerted HO-1-mediated reduction of oxidative stress and anti-inflammation in BMMSCs, as these effects were reversed by ZnPP pretreatment [1].
|
|---|---|
| ln Vivo |
PIISVYWK (1–10 mg/kg; orally; daily; 15 weeks) significantly reduced body weight gain, fat accumulation and pro-inflammatory cytokines in HFD-induced obese mice at a dose of 10 mg/kg, while activating anti-obesity and antioxidant pathways, with moderate effects at a dose of 1 mg/kg [1].
|
| Animal Protocol |
Animal/Disease Models:C57BL/6 (male, 3 weeks old at the start of adaptation, 6 weeks old at the start of study, high-fat diet-induced obesity model) [1]
Doses: 1 mg/kg; 10 mg/kg Route of Administration: Oral; daily; 15-week Experimental Results: Weight gain decreased to 17.29 grams, body fat percentage decreased to 45.26%, adipose tissue weight decreased, adipogenic transcription factors (PPARγ, SREBP-1, C/EBPα) and adipogenic enzymes (LPL, FAS, aP2) in subcutaneous adipose tissue were inhibited, p-HSL and p-AMPK expression in subcutaneous adipose tissue increased, fasting blood glucose decreased to 146.00 mg/dL, total cholesterol (4.98 mmol/L), low-density lipoprotein cholesterol (1.00 mmol/L) and triglycerides (1.43 mmol/L) decreased, high-density lipoprotein cholesterol (1.49 mmol/L) and free glycerol levels increased, and serum pro-inflammatory cytokines (IL-6: 34.33 picograms/mL, IL-1β: 17.00 picograms/mL) decreased. TNFα: 22.67 pg/mL), increased antioxidant enzyme activity (CAT: 35.4 U/mL, SOD: 165.2 U/mL, GPx: 82.7 U/mL), HO-1 and Nrf2 in subcutaneous adipose tissue were activated at a dose of 10 mg/kg; increased body weight, decreased fasting blood glucose, LDL, and pro-inflammatory cytokines, and increased antioxidant enzyme activity were observed, which were activated at a dose of 1 mg/kg. |
| References |
| Molecular Formula |
C51H76N10O11
|
|---|---|
| Molecular Weight |
1005.21
|
| CAS # |
2016043-80-2
|
| Sequence |
Pro-Ile-Ile-Ser-Val-Tyr-Trp-LysPIISVYWK
|
| SequenceShortening |
PIISVYWK
|
| Appearance |
Typically exists as solids at room temperature
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.9948 mL | 4.9741 mL | 9.9482 mL | |
| 5 mM | 0.1990 mL | 0.9948 mL | 1.9896 mL | |
| 10 mM | 0.0995 mL | 0.4974 mL | 0.9948 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
